CSBR : Summary for CHAMPIONS ONCOLOGY - Yahoo Finance

U.S. Markets close in 46 mins.

Champions Oncology, Inc. (CSBR)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.35-0.02 (-0.59%)
As of 3:12PM EST. Market open.
People also watch
CRTNCLRBCBIOCTRVCGNT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close3.37
Open3.40
Bid3.29 x 300
Ask3.37 x 300
Day's Range3.21 - 3.45
52 Week Range1.11 - 4.79
Volume65,046
Avg. Volume178,219
Market Cap36.74M
Beta-0.05
PE Ratio (TTM)-3.80
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire5 days ago

    Champions Oncology Announces New Collection of Patient-Derived Xenograft (PDX) Models Available for Translational Research

    HACKENSACK, N.J., Feb. 16, 2017 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), a company engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs, today announced the addition of new cohorts of PDX models to their existing TumorBank. "Champions continues to invest in building new models that reflect the evolving standard of care to provide robust model cohorts for pre-clinical research and clinical trial simulation.

  • PR Newswirelast month

    Champions Oncology Retains Hayden IR to Execute Comprehensive Investor Relations Program

    HACKENSACK, N.J., Jan. 19, 2017 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it has retained Hayden IR, a premier national investor relations consulting firm, to develop and execute strategic investor relations campaigns designed to increase awareness and enhance shareholder value. Ronnie Morris, CEO of Champions Oncology, commented, "Having achieved profitability in our fiscal second quarter, with 50% year-over-year quarterly revenue growth and an annual revenue growth rate target of 43-60%, fiscal 2017 is poised to be a transformational year for Champions Oncology.

  • Champions Oncology, Inc. :CSBR-US: Earnings Analysis: Q2, 2017 By the Numbers : December 16, 2016
    Capital Cube2 months ago

    Champions Oncology, Inc. :CSBR-US: Earnings Analysis: Q2, 2017 By the Numbers : December 16, 2016

    Categories: Yahoo Finance Get free summary analysis Champions Oncology, Inc. reports financial results for the quarter ended October 31, 2016. We analyze the earnings along side the following peers of Champions Oncology, Inc. – Aviragen Therapeutics Inc, Charles River Laboratories International, Inc., Exelixis, Inc., Heska Corporation, NanoString Technologies, Inc., Celldex Therapeutics, Inc., BiOptix, Inc. and Foundation Medicine, Inc. ... Read more (Read more...)